1-butylaminoadamantane | 3717-50-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-butylaminoadamantane
• 英文别名: N-n-butylamantadine；<1>Adamantyl-butyl-amin；1-Butylaminoadamantan；N-butyladamantan-1-amine
• CAS: 3717-50-8
• 化学式: C₁₄H₂₅N
• mdl: MFCD11140713
• 分子量: 207.359
• InChiKey: BAJOPXDPTLCURP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-butylaminoadamantane 以 环己烷 为溶剂， 生成 (3-Adamantan-1-yl-3-butyl-ureido)-acetic acid
  参考文献：
  名称：

  DE2052256

  摘要：

  公开号：
• 作为产物：
  描述：

  1-溴金刚烷 在 lithium aluminium tetrahydride 、 硫酸 作用下， 以 乙二醇二甲醚 为溶剂， 生成 1-butylaminoadamantane
  参考文献：
  名称：

  抗病毒药。2.与1-金刚烷胺有关的化合物的构效关系。

  摘要：

  DOI：

  10.1021/jm00288a019

文献信息

• Benzimidazole derivatives and their use as a medicament
  申请人：Poitout Lydie

  公开号：US20090170922A1

  公开（公告）日：2009-07-02

  A subject of the present application is new benzimidazole derivatives of formula in which A, Y, R 1 , R 2 , R 3 and R 4 represent different variable groups. These products have an antagonist activity of GnRH (Gonadotropin-Releasing Hormone). The invention also relates to pharmaceutical compositions containing said products and their use for the preparation of a medicament.

  本申请的主题是公式中A、Y、R1、R2、R3和R4代表不同变量基团的新苯并咪唑衍生物。这些产物具有GnRH（促性腺激素释放激素）的拮抗活性。本发明还涉及含有所述产物的制药组合物及其用于制备药物的用途。
• High Fidelity Kinetic Self-Sorting in Multi-Component Systems Based on Guests with Multiple Binding Epitopes
  作者：Pritam Mukhopadhyay、Peter Y. Zavalij、Lyle Isaacs

  DOI：10.1021/ja063390j

  日期：2006.11.1

  The molecular recognition platforms of natural systems often possess multiple binding epitopes, each of which has programmed functional consequences. We report the dynamic behavior of a system comprising CB[6], CB[7], and guests cyclohexanediammonium (1) and adamantanealkylammonium (2) that we refer to as a two-faced guest because it contains two distinct binding epitopes. We find that the presence of the two-faced guests-just as is observed for protein targeting in vivo-dictates the kinetic pathway that the system follows toward equilibrium. The influence of two-faced guest structure, cation concentration, cation identity, and individual rate and equilibrium constants on the behavior of the system was explored by a combination of experiment and simulation. Deconstruction of this system led to the discovery of an anomalous host-guest complex (CB[6]center dot 1) whose dissociation rate constant (k(out) = 8.5 x 10(-10) s(-1)) is approximate to 100-fold slower than the widely used avidin, biotin affinity pair. This result, in combination with the analysis of previous systems which uncovered extraordinarily tight binding events (K-a >= 10(12) M-1), highlights the inherent potential of pursuing a systems approach toward supramolecular chemistry.
• Adamantylamides of 1,3-diphenylpyrazole-4-carboxylic acids
  作者：I. S. Morozov、N. V. Klimova、N. P. Bykov、N. M. Zaitseva、G. V. Pushkar'、É. D. Dvalishvili、A. A. Khranilov、B. M. Pyatin

  DOI：10.1007/bf00772017

  日期：1991.3
• MOROZOV, I. S.;KLIMOVA, N. V.;BYKOV, N. P.;ZAJTSEVA, N. M.;PUSHKAR, G. V.+, XIM.-FARMATS. ZH., 25,(1991) N, S. 29-31
  作者：MOROZOV, I. S.、KLIMOVA, N. V.、BYKOV, N. P.、ZAJTSEVA, N. M.、PUSHKAR, G. V.+

  DOI：——

  日期：——
• NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION
  申请人：Enanta Pharmaceuticals, Inc.

  公开号：US20160136233A1

  公开（公告）日：2016-05-19

  The present invention relates to novel cyclosporine analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporine analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.